PhotoCure ASA PHCUF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
PhotoCure ASA is a Norway based specialty pharmaceutical company. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. The operating segments of the group are the Commercial franchise and Development portfolio. The company markets product through its commercial operation in the Nordic region under the brand name Hexvix and in the US under the brand name Cysview. It generates prime revenue from the Commercial franchise segment which includes the Hexvix and Cysview products.
Oslo, NO-0275, Norway